ANIP: ANI Pharmaceuticals, Inc. - Summary | Jitta

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Price
$32.70
Loss Chance
46.9%
3.62JITTA SCORE
10.42%Under Jitta Line
Jitta Ranking
56 / 1,041
969 / 4,594
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (55)
Recent Business Performance (68)
Financial Strength (59)
Return to Shareholders (21)
Competitive Advantage (54)
Jitta Signs
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
Debt LevelVery High Long Term Debt
Recent Business PerformanceEarning decline 121.54% in the last year
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.62
10.42%
2.04
285.53%
2.25
348.40%
Pharmaceuticals
5.17
1.53%
4.51
44.38%
4.47
14.32%
COMPANY DESCRIPTION
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.